Pfizer Culture d’entreprise

Dr. Mikael Dolsten, MD, Ph.D., has been the President of Worldwide Research and Development at Pfizer Inc. since December 2010 and has been its Executive VP since June 13, 2017. Dr. Dolsten serves as an Executive Vice President of Pfizer Inc. Dr. Dolsten also serves as a Member of Pfizer Executive Leadership Team. Dr. Dolsten serves as the President of Worldwide Research and Development at Pfizer Limited. Prior to joining Pfizer in 2009, he served as Senior Vice President of Wyeth and President of Wyeth Research, where he was responsible for the global R&D division and led scientists across the US, Europe and Asia. Before joining Wyeth, he served as an Executive Vice President at Boehringer Ingelheim, where he was responsible for worldwide research including activities at R&D sites in the US, Canada, Germany, Italy, Austria and Japan. He served as Head of Corporate Division Pharma Research/Discovery at Boehringer Ingelheim with responsible for approximately 1400 discovery scientists and world-wide research in respiratory, immunology/inflammation, metabolic disease, CNS/pain, oncology and cardiovascular therapies. Dr. Dolsten was a Partner at OrbiMed Advisors, L.L.C. He held various senior R&D management positions including: Head of Preclinical Research Oncology/Immunology at Pharmacia & Upjohn, Lund and Head of Preclinical R&D, Vice President of Respiratory and Inflammation at Astra Draco, Lund. In addition, he gained leadership experience from five large-scale M&A transactions. He served as the President of BioTherapeutics Research & Development at Pfizer Inc. from October 2009 to May 2010 and served as its Senior Vice President from May 2010 to December 2010. Prior to joining Boehringer Ingelheim in 2003, Dr. Dolsten was responsible for integrating several areas of AstraZeneca Discovery post-merger. He also served as Global Vice President/Head of Cardiovascular/Metabolic & Gastrointestinal Discovery at AstraZeneca. Dr. Dolsten has spent approximately seventeen years in the pharmaceutical Industry. He has been Chairman, Translational Advisory Board of Apple Tree Partners since 2016. Dr. Dolsten has been an Independent Director at Karyopharm Therapeutics Inc. since March 31, 2015. He serves as a Member of Translational Advisory Board at Apple Tree Partners. He serves as a Member of MDL Scientific Advisory Board at Elsevier B.V. He served as a Director of Receptos, Inc. He is a Member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA) and serves on the PhRMA Foundation Board of Directors. He has been a Board Member of a Swedish Business School for Innovation and Chamber of Commerce. He is a Governor of the New York Academy of Sciences. He was appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden. He was Associate Professor at Lund University since 1989 and Adjunct Professor in Cell and Molecular Biology since 1996. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology. He earned his Ph.D. in Tumor Immunology and M.D. from the University of Lund in Sweden. He also studied Virology and Cell Biology at the Weizmann Institute in Israel.

Mr. John D. Young has been the Group President of Pfizer Innovative Health at Pfizer Inc. since January 1, 2018 and served as its Group President of Pfizer Essential Health from June 2016 to January 1, 2018. Mr. Young is a Director of Johnson Controls International plc from December 2017. He served as a Group President of Global Established Pharma Business at Pfizer Inc. from January 1, 2014 to June 2016. Mr. Young served as President and General Manager of Primary Care Business Unit at Pfizer Inc. from June 1, 2012 to December 2013 and U.K. Country Manager from 2007 until 2009. He served as Regional President of Europe and Canada for The Primary Care Business at Pfizer Inc. from 2009 to June 1, 2012. Over his 25-year career with Pfizer, he served a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the United Kingdom. He is a scientist by training and has deep knowledge of the company's innovative biopharmaceutical portfolio having led the commercial and clinical development of medicines in key therapeutic areas including cardiovascular disease, diabetes and pain. Mr. Young received a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.

Frank A. D'Amelio has served as a Director of Humana Inc. since September 2003. He is Executive Vice President, Business Operations and Chief Financial Officer of Pfizer Inc., having held this position since December 2010, and having served as Chief Financial Officer since September 2007. Prior to that, Mr. D'Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent from December 2006 to August 2007, and Chief Operating Officer of Lucent Technologies Inc. from February 2006 to November 2006. From May 2001 until January 2006, he was Executive Vice President, Administration and Chief Financial Officer of Lucent. Mr. D'Amelio also serves on the Board of Directors of Zoetis, Inc. and on the board of the Independent College Fund of New Jersey.

Dr. Kathrin U. Jansen, Ph.D. has been Senior Vice President of Vaccine Research & Development at Pfizer Inc. since June 01, 2015. Dr. Jansen served as Senior Vice President of Early Phase Programs of Vaccine Research at Wyeth LLC. Dr. Jansen served as Senior Vice President of Research and Development and Chief Scientific Officer of VaxGen Inc., from October 19, 2004 to July 29, 2006. Dr. Jansen lead an organization of approximately 550 colleagues comprised of clinicians, vaccine process/analytical/and formulation development, and other laboratory scientists. Dr. Jansen joined VaxGen in October 2004 after having served as Executive Director of Microbial Vaccine Research for Merck Research Laboratories. At Vaxgen, Dr. Jansen leads a team of more than 40 scientists and related personnel in developing Vaxgen's existing investigational vaccines, as well as evaluating and developing new product candidates. Dr. Jansen was the scientific leader of the team that successfully developed Merck's Phase III human papillomavirus (HPV) vaccine candidate to prevent genital warts and cervical cancer. Additionally, she was responsible for several bacterial vaccine programs at Merck. Dr. Jansen also headed the clinical assay laboratory responsible for the development and validation of new assays and for the clinical testing of all existing Merck accines and vaccine candidates. Dr. Jansen joined Merck in 1992 as a research fellow and advanced through a series of positions with increasing responsibility. Prior to Merck, she served from 1989 to 1992 as a research scientist at the Glaxo Institute for Molecular Biology, where she studied the structure and function of a low affinity receptor for IgE (CD23). Prior to her career in industry, Dr. Jansen held research positions at Cornell University and Institut fur Mikrobiologie, Marburg, Germany. She is an author on 53 scientific articles and the inventor on seven issued patents and numerous patent applications related to vaccine research and development. She holds a Ph.D. in Microbiology, with a minor in Biochemistry and Genetics and an undergraduate degree in Biology from Philipps-Universitat, Marburg, Germany.

Mr. Hugh Donnelly serves as the Chief Internal Auditor of Pfizer Inc. and served as its Vice President of Corporate Audit. Mr. Donnelly assumed this position in July, 2002 and is responsible for leading 120 audit professionals primarily based in New York, New Jersey, Connecticut, Pennsylvania, Mumbai and Dublin. Corporate Audit provides independent, Pan-Pfizer corporate regulatory audit and oversight of processes and systems spanning its operating model including: discovery, development, manufacturing, commercial sales & marketing activities, finance and information technology. Previously, he was Assistant Controller, Pfizer Inc. with responsibility for Pfizer's Financial Shared Services. He served US Treasury operations and European finance roles in Corporate Treasury. Hugh joined Pfizer as Controller of the acquired SmithKline Beecham Animal Health business in 1995. Hugh has held numerous other financial positions in commercial operations, manufacturing and corporate finance over a 25+ year career in the pharmaceutical industry. Hugh is CPA who started his career with PriceWaterhouse Coopers/Coopers & Lybrand. He holds a BS in Accounting from Villanova University.

Susan Silbermann has been President of Global Vaccines Business and General Manager of Global Vaccines Business at Pfizer Inc., since January 1, 2014. Susan Silbermann serves as the Regional President, Latin America at Emerging Markets Business Unit of Pfizer Inc. Susan Silbermann serves as a Member of the Advisory Board at Catalyst Inc.

Ms. Loretta V. Cangialosi has been a Senior Vice President and Controller of Pfizer, Inc since February 1993 and served as its Vice President. Ms. Cangialosi serves as a Member of Standing Advisory Group at Public Company Accounting Oversight Board (PCAOB).

Dr. Michael Vincent, M.D., Ph.D. has been Senior Vice President and Chief Scientific Officer of Inflammation and Immunology Research Unit at Pfizer Inc. since May 2016. Since joining Pfizer in 2011, Dr. Vincent served numerous scientific leadership roles, served as Clinical Head for Pharmatherapeutics and Biotherapeutics. Before joining Pfizer, Dr. Vincent served several positions within Medical Sciences at Amgen. He also served as a staff physician at Harvard University. Dr. Vincent earned his Ph.D. and M.D. degrees from Indiana University. He completed his residency and began his post-doctoral training at the University of Vermont and ultimately completed at Harvard University.